Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Argus Health
UBS
Deloitte
Citi
McKinsey
US Department of Justice
Harvard Business School
Johnson and Johnson

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OMONTYS

« Back to Dashboard

Clinical Trials for Omontys

Trial ID Title Status Sponsor Phase Summary
NCT00097747 Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers Completed Affymax Phase 1 The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers.
NCT00109291 Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease Terminated Affymax Phase 2 To evaluate the safety profile of single intravenous (IV) dose levels of peginesatide in participants with chronic kidney disease(CKD) not on dialysis.
NCT00228436 Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients Completed Affymax Phase 2 The purpose of this study was to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneous injections of peginesatide in participants with chronic kidney disease (CKD) not on dialysis who had not received erythropoiesis stimulating agent (ESA) treatment.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Omontys

Condition Name

Condition Name for Omontys
Intervention Trials
Anemia 17
Chronic Kidney Disease 14
Chronic Renal Failure 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Omontys
Intervention Trials
Renal Insufficiency 14
Kidney Failure, Chronic 14
Kidney Diseases 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Omontys

Trials by Country

Trials by Country for Omontys
Location Trials
United States 160
United Kingdom 10
Poland 5
Romania 4
Bulgaria 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Omontys
Location Trials
Texas 10
California 10
New York 8
Florida 8
Virginia 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Omontys

Clinical Trial Phase

Clinical Trial Phase for Omontys
Clinical Trial Phase Trials
Phase 4 1
Phase 3 5
Phase 2 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Omontys
Clinical Trial Phase Trials
Completed 14
Terminated 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Omontys

Sponsor Name

Sponsor Name for Omontys
Sponsor Trials
Affymax 16
Takeda 9
Amgen 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Omontys
Sponsor Trials
Industry 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Fish and Richardson
Boehringer Ingelheim
Moodys
Chubb
AstraZeneca
Baxter
Accenture
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.